Raltegravir pharmacokinetics during pregnancy

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 4, 2014, Pages 375-381

  Watts, D Heather ^a   Stek, Alice ^b   Best, Brookie M ^c   Wang, Jiajia ^d   Capparelli, Edmund V ^c   Cressey, Tim R ^e   Aweeka, Francesca ^f   Lizak, Patty ^f   Kreitchmann, Regis ^g   Burchett, Sandra K ^h   Shapiro, David E ^d   Hawkins, Elizabeth ⁱ   Smith, Elizabeth ^j   Mirochnick, Mark ^k  

^a U S DEPARTMENT OF STATE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^e CHIANG MAI UNIVERSITY   (Thailand)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Irmandade da Santa Casa de Misericordia de Porto Alegre   (Brazil)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

HIV; Pharmacokinetics; Pregnancy; Raltegravir

Indexed keywords

MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; 2 PYRROLIDONE DERIVATIVE; INTEGRASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; PHARMACOKINETICS; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; UMBILICAL CORD BLOOD; VOLUME OF DISTRIBUTION; VOMITING; BLOOD; HIV INFECTIONS; METABOLISM; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

ADULT; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTERS; PYRROLIDINONES; YOUNG ADULT;

EID: 84922481121     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000318     Document Type: Conference Paper

References (17)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL. pdf, Page F-1. Accessed January 30, 2014.
2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed January 30, 2014.
3. Westling K, Pettersson K, Kaldma A, et al. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS. 2012;26:714-717.
4. Jaworsky D, Thompson C, Yudin MH, et al. Use of newer antiretroviral agents, darunavir and etravirine, with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther. 2010;15:677-680.
5. Mckeown DA, Rosenvinge M, Donaghy S, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS. 2010;24:2416-2418.
6. Pinetti C, Baroncelli S, Villani P, et al. Rapid HIV-RNA decline following addition of raltegraivr and tenofovir to ongoing active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother. 2010;65:2050-2052.
7. Croci L, Trezzi M, Allegri MP, et al. Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol. 2012;68:123-132.
8. Jeantils V, Messaouden H, Carbillon L. Pregnancy and a regimen containing raltegravir: a pilot study on the materno-foetal safety. Paper presented at: The 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12, 2013; Denver, CO, Abstract H-1463.
9. Raltegravir [package insert]. Available at: http://www.merck.com/product/usa/pi-circulars/i/isentress/isentress-pi.pdf. Accessed February 3, 2014.
10. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20:1931-1939.
11. Renet S, Closon A, Brochet MS, et al. Increase in transaminase levels following the use of raltegrair in a woman with a high HIV viral load at 35 weeks of pregnancy. J Obstet Gynaecol Can. 2013;35:68-72.
12. Wohl DA, Dumond JB, Blevins S, et al. Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. Antimicrob Agents Chemother. 2013;57:784-788.
13. Eron JJ Jr, Rockstroh JK, Reynes J, et al; The QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011;11:907-915.
14. Wenning L, Hwang E, Nguyen BY, et al. Pharmacokinetic/pharmacodynamics (PK/PD) analyses for raltegravir (RAL) in phase III studies in treatment experienced HIV-infected patients following 48 weeks of treatment. Paper presented at: The 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Disease Society of America Meeting; October 28, 2008, Washington, D.C. Abstract H4054. Available at: http://www.abstractsonline.com/viewer/SearchResults. asp. Accessed February 3, 2014.
15. Iowamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenze on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008;52:4338-4343.
16. Iowamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increased plasma levels of raltegraivr in healthy subjects. Clin Infect Dis. 2008;47:137-140.
17. Andrade A, Rosenkranz Sl, Cillo AR, et al; AIDS Clinical Trials Group A5248 Team. Three distinct phases of HIV-1 RNA decay in treatmentnaive patients receiving raltegravir-based antiretroviral therapy: ACTG 5248. J Infect Dis. 2013;208:884-891.